Keros Therapeutics (KROS) EPS (Weighted Average and Diluted) (2020 - 2025)
Keros Therapeutics (KROS) reported EPS (Weighted Average and Diluted) of -$0.38 for Q4 2025, up 66.07% on a YoY basis from -$0.23 in Q4 2024, and down 111.11% quarter-over-quarter from -$0.18 in Q3 2025.
Keros Therapeutics (KROS) EPS (Weighted Average and Diluted) (2020 - 2025) Analysis & Trends
Keros Therapeutics has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.38 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 66.07% year-over-year to -$0.38; the trailing twelve-month figure through Dec 2025 stood at $2.3 (up 146.09% YoY), and the FY2025 full-year result was $2.3, up 146.0% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.38, down from -$0.18 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $3.62 in Q1 2025, with the low at -$1.41 in Q3 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.73 across 5 years, with a median of -$1.06 in 2022.
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) tumbled 266.67% — and 2025, when it surged 399.17%.
- Keros Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.3 in 2021, then plunged by 266.67% to -$1.1 in 2022, then decreased by 21.82% to -$1.34 in 2023, then grew by 16.42% to -$1.12 in 2024, then soared by 66.07% to -$0.38 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.38 (Q4 2025), -$0.18 (Q3 2025), and -$0.76 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | -0.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.38 |
| Sep 30, 2025 | -0.18 |
| Jun 30, 2025 | -0.76 |
| Mar 31, 2025 | 3.62 |
| Dec 31, 2024 | -1.12 |
| Sep 30, 2024 | -1.41 |
| Jun 30, 2024 | -1.25 |
| Mar 31, 2024 | -1.21 |
| Dec 31, 2023 | -1.34 |
| Sep 30, 2023 | -1.33 |
| Jun 30, 2023 | -1.27 |
| Mar 31, 2023 | -1.26 |
| Dec 31, 2022 | -1.10 |
| Sep 30, 2022 | -0.92 |
| Jun 30, 2022 | -1.13 |
| Mar 31, 2022 | -1.01 |
| Dec 31, 2021 | -0.30 |
| Sep 30, 2021 | -0.87 |
| Jun 30, 2021 | -0.67 |
| Mar 31, 2021 | -0.68 |